Jian Yin

Jian Yin


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2024 in European Journal of Neurology
Verified
Journal Article
Open access
JYJian Yin
Jian Yin
MZMingming Zhao
Mingming Zhao
XXXianhao Xu
Xianhao Xu
MZMeini Zhang
Meini Zhang
ZXZucai Xu
Zucai Xu
JFJianmin Fang
Jianmin Fang
Background and purpose: This study aimed to investigate the clinical efficacy and safety of telitacicept in patients with generalized myasthenia gravis (gMG) who tested positive for acetylcholine receptor antibodies or muscle‐specific kinase antibodies and were receiving standard‐of‐care therapy.Methods: Patients meeting the eligibility criteria were randomly assigned to receive telitacicept subcutaneously once a week for 24 weeks in addition to standard‐of‐care treatment. The primary efficacy endpoint was the mean change in the quantitative myasthenia gravis (QMG) score from baseline to week 24. Secondary efficacy endpoints included mean change in QMG score from baseline to week 12 and gMG clinical absolute score from baseline to week 24. Additionally, safety, tolerability and pharmacodynamics were assessed.Results: Twenty‐nine of the 41 patients screened were randomly selected and enrolled. The mean (± standard deviation [SD]) reduction in QMG score from baseline to week 24 was 7.7 (± 5.34) and 9.6 (± 4.29) in the 160 mg and 240 mg groups, respectively. At week 12, mean reductions in QMG scores for these two groups were 5.8 (± 5.85) and 9.5 (± 5.03), respectively, indicating rapid clinical improvement. Safety analysis revealed no adverse events leading to discontinuation or mortalities. All patients showed consistent reductions in serum immunoglobulin (Ig) A, IgG and IgM levels throughout the study.Conclusion: Telitacicept demonstrated safety, good tolerability and reduced clinical severity throughout the study period. Further validation of the clinical efficacy of telitacicept in gMG will be conducted in an upcoming phase 3 clinical trial.

11 June 2024 in Bioengineering
Verified
Journal Article
Open access
PDF file
JLJianqiang Li
Jianqiang Li
CZChujie Zhu
Chujie Zhu
MZMingming Zhao
Mingming Zhao
XXXi Xu
Xi Xu
LZLinna Zhao
Linna Zhao
JYJian Yin
Jian Yin
This paper presents an eye image segmentation-based computer-aided system for automatic diagnosis of ocular myasthenia gravis (OMG), called OMGMed. It provides great potential to effectively liberate the diagnostic efficiency of expert doctors (the scarce resources) and reduces the cost of healthcare treatment for diagnosed patients, making it possible to disseminate high-quality myasthenia gravis healthcare to under-developed areas. The system is composed of data pre-processing, indicator calculation, and automatic OMG scoring. Building upon this framework, an empirical study on the eye segmentation algorithm is conducted. It further optimizes the algorithm from the perspectives of “network structure” and “loss function”, and experimentally verifies the effectiveness of the hybrid loss function. The results show that the combination of “nnUNet” network structure and “Cross-Entropy + Iou + Boundary” hybrid loss function can achieve the best segmentation performance, and its MIOU on the public and private myasthenia gravis datasets reaches 82.1% and 83.7%, respectively. The research has been used in expert centers. The pilot study demonstrates that our research on eye image segmentation for OMG diagnosis is very helpful in improving the healthcare quality of expert doctors. We believe that this work can serve as an important reference for the development of a similar auxiliary diagnosis system and contribute to the healthy development of proactive healthcare services.

9 August 2023 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
JWJiexi Wen
Jiexi Wen
WSWen Su
Wen Su
LZLei Zhang
Lei Zhang
RHRu Huang
Ru Huang
JYJian Yin
Jian Yin
KLKai Li
Kai Li

12 January 2026 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
YYYufang Yang
Yufang Yang
TLTao Liang
Tao Liang
MZMingming Zhao
Mingming Zhao
HYHongxia Yang
Hongxia Yang
ZZZhilan Zhao
Zhilan Zhao
ZLZhong Luo
Zhong Luo
Background: Efgartigimod, a neonatal Fc receptor (FcRn) blocker, is approved for generalized Myasthenia Gravis (gMG), but predictors of early response are unclear. Using minimal symptom expression (MSE) as the therapeutic target, we developed and externally validated a clinical model to predict early MSE response after starting efgartigimod. This efgartigimod‐tailored model estimates the baseline probability of achieving early MSE and may assist in individualized treatment selection at therapy initiation. Methods: We retrospectively analyzed 118 adults with gMG treated at five tertiary centers in China (efgartigimod 10 mg/kg IV weekly ×4). MSE was defined as Myasthenia Gravis–Activities of Daily Living (MG‐ADL) ≤ 1 sustained ≥ 4 weeks; early MSE response was achievement within 4 weeks of initiation. Patients were split into a derivation cohort ( n = 64; three centers) and an external validation cohort ( n = 54; two centers). Candidate predictors included demographics, baseline severity, and laboratory indices. Variables associated with early MSE in univariable analyses entered multivariable logistic regression to construct a nomogram. Discrimination (AUC‐ROC), calibration (curves and Spiegelhalter Z ‐test), and clinical utility (decision curve analysis, DCA) were assessed, with bootstrap internal validation. Results: Early MSE response occurred in 26/64 derivation and 22/54 validation patients. Lower bulbar MG‐ADL (OR 0.633, p = 0.040), higher FVC% (OR 1.042, p = 0.048), and lower IgG (OR 0.795, p = 0.036) independently predicted early MSE response. The nomogram showed strong discrimination—derivation AUC 0.869 (95% CI 0.797–0.941), bootstrap AUC 0.880 (0.806–0.954), and external AUC 0.839 (0.760–0.919)—and good calibration (Spiegelhalter Z : 1.03, p = 0.303; 0.94, p = 0.347; 1.17, p = 0.242). DCA indicated net benefit across thresholds 0.05–0.82, with validation curves mirroring derivation. Conclusions: A three‐factor nomogram (bulbar MG‐ADL, FVC%, and serum IgG) provides an efgartigimod‐specific baseline estimate of early sustained‐MSE response probability, which may help neurologists select appropriate candidates, counsel expected benefit, and tailor follow‐up intensity or alternative escalation strategies. Trail Registration: Chinese Clinical Trial Registry (ChiCTR2500101971)

28 February 2026 in Artificial Intelligence Surgery
Verified
Journal Article
Open access
PDF file
XXXi Xu
Xi Xu
YZYing Zhang
Ying Zhang
QNQiufei Niu
Qiufei Niu
NLNianjiao Long
Nianjiao Long
JLJianqiang Li
Jianqiang Li
Ji-Jiang YangJi-Jiang Yang
Ji-Jiang Yang
Background: Speech production is a coordinated physiological process and a vital digital biomarker for health assessment. Recent advances in artificial intelligence (AI), particularly in representation learning, have substantially expanded the application of speech analysis across diverse clinical domains. Methods: This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). Five major bibliographic databases were systematically searched for studies published between 2015 and 2025. Eligible studies applied AI-driven speech analysis for clinical diagnosis or monitoring, while those lacking quantitative evaluation or sufficient methodological detail were excluded. Results: A total of 124 studies were analyzed, covering neurological, psychiatric, and respiratory disorders. The field has transitioned from traditional machine learning with handcrafted features to deep learning and foundation models. Parkinson’s disease, Alzheimer’s disease, depression, and coronavirus disease 2019 (COVID-19) are the most frequently investigated conditions. The included studies were charted and synthesized to map disease coverage, methodological trends, and clinical application scenarios. Conclusion: Speech analysis offers a non-invasive approach for early disease detection and remote monitoring in telemedicine. To support clinical translation, future research should prioritize model robustness and interpretability across diverse clinical populations.

7 October 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
BYBin Yang
Bin Yang
JWJing Wang
Jing Wang
XZXiuli Zhao
Xiuli Zhao
CJChuya Jing
Chuya Jing
JYJian Yin
Jian Yin
LQLiyan Qiao
Liyan Qiao
Introduction: Eculizumab, an antibody that inhibits the complement system, and the immunosuppressant Tacrolimus are both authorized for treating patients with generalized myasthenia gravis (GMG). This study seeks to evaluate and compare the clinical effectiveness of Eculizumab with or with not Tacrolimus in the treatment of generalized myasthenia gravis. Methods: A retrospective study was performed involving 95 patients with GMG treated with Eculizumab at three hospitals in China. Among them, 80 patients were included in the analysis: 57 received Eculizumab alone, while 23 were treated with a combination of Eculizumab and Tacrolimus. The main outcome assessed was the percentage of GMG patients who reached Minimal Symptom Expression (MSE). Secondary outcomes included changes in MG-Activities of Daily Living (MG-ADL) scale, Quantitative Myasthenia Gravis (QMG) score, CH50 concentration, and doses of pyridostigmine and prednisolone. Additionally, the safety profiles of both treatment groups were examined. Results: In the main outcome, a higher proportion of patients reached MSE status when treated with a combination of Eculizumab and Tacrolimus compared to Eculizumab alone (Eculizumab: 29 patients, 50.9% vs Eculizumab and Tacrolimus: 18 patients, 78.3%; p0.05). The decrease in complement CH50 concentration is accompanied by a decrease in QMG and MG-ADL scores, indicating that Eculizumab treats GMG through the mechanism of complement system. In terms of security, hyperuricemia was more commonly associated with the combination therapy of Eculizumab and Tacrolimus than with Eculizumab alone. Conclusion: Our research indicates that Eculizumab can effectively reduce disability in GMG patients by inhibiting complement system activation under real-world clinical conditions in China. We observed a correlative link between Eculizumab and Tacrolimus combination treatment and an increased probability of achieving MSE status, in comparison with Eculizumab monotherapy. However, combination therapy is associated with a higher risk of elevated serum uric acid among GMG patients, which necessitates regular close monitoring of renal function.